B cell receptor-mediated lentiviral expression of anti-HIV antibody
Grant Award Details
Grant Type:
Grant Number:
DISC2-16725
Investigator(s):
Disease Focus:
Award Value:
$2,751,504
Status:
Active
Grant Application Details
Application Title:
B cell receptor-mediated lentiviral expression of anti-HIV antibody
Public Abstract:
Research Objective
With a single administration to an individual, lentiviral vectors that selectively transduce B cells in vivo and express highly potent anti-HIV-1 proteins to suppress HIV-1 replication throughout life
Impact
HIV infection can lead to AIDS if not continuously managed with medication and care. We are developing gene therapy vectors that can suppress and possibly eradicate HIV-1 by a single administration.
Major Proposed Activities
With a single administration to an individual, lentiviral vectors that selectively transduce B cells in vivo and express highly potent anti-HIV-1 proteins to suppress HIV-1 replication throughout life
Impact
HIV infection can lead to AIDS if not continuously managed with medication and care. We are developing gene therapy vectors that can suppress and possibly eradicate HIV-1 by a single administration.
Major Proposed Activities
- Characterization of the properties of B cell specific lentiviral vectors and analyze innate and acquired immune responses against the vectors
- Targeted transduction of B cells in humanized BLT mice
- Optimize the vector structure and the amount of vector administration necessary for maximal production and antiviral effects of eCD4-Ig
- Examine preventive effects of B cell targeting lentiviral vectors expressing eCD4-Ig on HIV-1 replication
- Examine therapeutic effects of B cell targeting lentiviral vectors expressing eCD4-Ig on HIV-1
- Leverage BCR signaling in transduced B cells to enhance and prolong eCD4-Ig production
Statement of Benefit to California:
Currently, there are an estimated 150,900 people living with HIV (PLWH) in California. Each year, California sees approximately 4,444 new cases of HIV infection, which can lead to AIDS if not properly managed with medication and care. Treating PLWH in California typically costs approximately $19,912/year per person. We are developing gene therapy vectors that can produce anti-HIV-1 antibody/antibody-like molecules after a single intravenous injection throughout life.
